SCHEMBL16320449

SCHEMBL16320449

Cc1cc(Nc2cc(C(N)=O)n[nH]2)nc(Nc2ccc(NC(=S)Nc3ccc(Cl)c(C(F)(F)F)c3)nc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.39
FLT3 P36888 4/20 0.39
KDR P35968 4/20 0.39
KIT P10721 2/20 0.39
RAF1 P04049 3/20 0.38
TEK Q02763 1/20 0.38
BTK Q06187 1/20 0.38
CDK8 P49336 3/20 0.38
LMNA P02545 1/20 0.38
CCNC P24863 1/20 0.38
EGFR P00533 1/20 0.38
IGF1R P08069 1/20 0.37
PDGFRB P09619 1/20 0.37
MAPK14 Q16539 1/20 0.37
GRM4 Q14833 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPK3 P27361 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16319693 0.93 BRAF (0.40) BRAFFLT3KDRKITRAF1
SCHEMBL27958196 0.93 KDR (0.40) BRAFFLT3KDRKITRAF1
SCHEMBL16319615 0.92 RAF1 (0.44) BRAFFLT3KDRRAF1TEK
SCHEMBL16320294 0.90 LMNA (0.41) BRAFFLT3KDRKITRAF1
SCHEMBL16319556 0.90 LMNA (0.42) BRAFFLT3KDRKITRAF1
SCHEMBL16320080 0.90 RAB9A (0.42) BRAFFLT3KDRKITRAF1
SCHEMBL16319911 0.89 BRAF (0.40) BRAFFLT3KDRKITRAF1
SCHEMBL16319532 0.89 IGF1R (0.44) BRAFFLT3KDRKITRAF1
SCHEMBL16320148 0.88 BRAF (0.41) BRAFFLT3KDRKITRAF1
SCHEMBL16320251 0.88 LMNA (0.41) BRAFFLT3KDRKITRAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9221798-B2 4-substituted-(3-substituted-1H-pyrazole-5-amino)-pyrimidine derivatives having activity of inhibiting protein kinase and use thereof Zhejian Hisun Pharmaceutical Co., Ltd. (CN) 2015-12-29 US disclosed
US-20140378488-A1 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378488-A1 4-SUBSTITUTED-(3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO)-PYRIMIDINE DERIVATIVES HAVING ACTIVITY OF INHIBITING PROTEIN KINASE AND USE THEREOF MAP4K2, MAP4K1, MAP4K3 BRAF 84/4885FLT3 235/4885KDR 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.